Fibromyalgia and MCAS: The Mast Cell–Neuroinflammation Connection

Introduction

Fibromyalgia and Mast Cell Activation Syndrome (MCAS) are two conditions that are increasingly recognized as frequent co-travelers in the same patients. Clinicians who specialize in either condition consistently report that a substantial proportion of their patients have both — and emerging research is beginning to explain why.

The connection lies in the intimate relationship between mast cells and the nervous system. Mast cells are not merely peripheral immune cells — they are densely distributed throughout the nervous system, they respond to neurotransmitters and neuropeptides, and they release mediators that directly sensitize pain receptors and modulate central pain processing. Understanding this mast cell–nerve axis is key to understanding why fibromyalgia and MCAS so often occur together.

---

The Mast Cell–Nerve Axis

Mast cells and nerve fibers exist in close anatomical proximity throughout the body. This is not coincidental — it reflects a functional relationship that has been conserved across evolution. Mast cells can be activated by:

• Substance P — a neuropeptide released by pain-sensing C-fibers
• Corticotropin-releasing hormone (CRH) — released during stress
• Nerve growth factor (NGF) — which also promotes mast cell survival and sensitization
• Norepinephrine — released by sympathetic nerve fibers

Conversely, activated mast cells release mediators that directly affect nerve function:

• Histamine — sensitizes pain receptors (nociceptors) and promotes neuroinflammation
• Tryptase — a protease that activates protease-activated receptor 2 (PAR2) on nociceptors, lowering their activation threshold
• Prostaglandins — sensitize peripheral and central pain pathways
• TNF-alpha and IL-6 — pro-inflammatory cytokines that contribute to central sensitization
• NGF — promotes nociceptor sensitization and sprouting

This bidirectional communication creates a potential amplification loop: pain activates mast cells, mast cells sensitize pain receptors, sensitized pain receptors generate more pain signal, which activates more mast cells.

---

Evidence for the Fibromyalgia–MCAS Overlap

Clinical co-occurrence

Studies examining the prevalence of MCAS symptoms in fibromyalgia patients have found rates of 30–50% depending on the diagnostic criteria used. Conversely, fibromyalgia-like widespread pain is reported by a significant proportion of MCAS patients.

The overlap is particularly striking in patients with hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD), where fibromyalgia, MCAS, and POTS frequently co-occur in what has been called the "hypermobility triad."

Shared biomarkers

Research has identified several biomarkers that are abnormal in both conditions:

• Elevated substance P in cerebrospinal fluid — found in fibromyalgia and may trigger mast cell activation
• Elevated tryptase — a mast cell activation marker found in some fibromyalgia patients
• Elevated histamine metabolites — found in subsets of fibromyalgia patients
• Elevated IL-6 and TNF-alpha — found in both conditions
• Small fiber neuropathy — present in subsets of both fibromyalgia and MCAS patients

Mast cells in fibromyalgia tissue

Skin biopsy studies in fibromyalgia patients have found increased mast cell density in the dermis, particularly around nerve fibers, compared to healthy controls. This anatomical finding supports the hypothesis that mast cell–nerve interactions contribute to the peripheral sensitization component of fibromyalgia.

---

Clinical Presentation of the Overlap

Patients with both fibromyalgia and MCAS often present with a particularly complex and multi-system symptom picture:

---

Treatment Implications

When fibromyalgia and MCAS co-occur, treatment must address both conditions. Treating only fibromyalgia while ignoring MCAS — or vice versa — typically produces incomplete results.

MCAS-first approach

In patients where MCAS symptoms are prominent (flushing, urticaria, GI reactions, anaphylaxis), addressing mast cell activation first can sometimes produce dramatic improvement in fibromyalgia symptoms. This supports the hypothesis that mast cell–driven neuroinflammation is a significant driver of central sensitization in these patients.

Key MCAS treatments with potential fibromyalgia benefit:

• H1 antihistamines (cetirizine, loratadine, fexofenadine) — reduce histamine-mediated sensitization
• H2 antihistamines (famotidine, ranitidine) — block H2 receptors on mast cells and nerve fibers
• Cromolyn sodium — mast cell stabilizer that may reduce neuroinflammation
• Ketotifen — mast cell stabilizer with H1 antihistamine properties; may have direct analgesic effects
• Quercetin — natural mast cell stabilizer with anti-neuroinflammatory properties

Fibromyalgia treatments with MCAS relevance

• Low-dose naltrexone (LDN) — reduces microglial activation and may also reduce mast cell activation through TLR4 antagonism
• Low-histamine diet — reduces the histamine load that contributes to both MCAS symptoms and pain sensitization
• Magnesium — mast cell stabilizing properties in addition to muscle relaxation and pain modulation

Shared treatment priorities

• Stress reduction — stress activates both the HPA axis (releasing CRH, which activates mast cells) and the sympathetic nervous system (releasing norepinephrine, which activates mast cells). Stress management is foundational for both conditions.
• Sleep optimization — histamine is a wakefulness-promoting neurotransmitter; MCAS-driven histamine excess disrupts sleep, which perpetuates fibromyalgia.
• Anti-inflammatory diet — reducing dietary triggers for mast cell activation can reduce the neuroinflammatory burden driving central sensitization.

---

Conclusion

The fibromyalgia–MCAS connection is not coincidental — it reflects shared mechanisms involving mast cell–nerve interactions, neuroinflammation, and central sensitization. For patients with both conditions, understanding this connection can guide a more targeted and effective treatment approach.

If you have fibromyalgia and also experience flushing, urticaria, GI reactions, or other symptoms suggestive of MCAS, discussing this overlap with a knowledgeable clinician may open new treatment avenues.

---

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment decisions.